Cargando…
Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future
People with diabetes are at greater risk for negative outcomes from COVID-19. Though this risk is multifactorial, poor glycaemic control before and during admission to hospital for COVID-19 is likely to contribute to the increased risk. The COVID-19 pandemic and restrictions on mobility and interact...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327601/ https://www.ncbi.nlm.nih.gov/pubmed/34338994 http://dx.doi.org/10.1007/s13300-021-01114-x |
_version_ | 1783732124026667008 |
---|---|
author | Danne, Thomas Limbert, Catarina Puig Domingo, Manel Del Prato, Stefano Renard, Eric Choudhary, Pratik Seibold, Alexander |
author_facet | Danne, Thomas Limbert, Catarina Puig Domingo, Manel Del Prato, Stefano Renard, Eric Choudhary, Pratik Seibold, Alexander |
author_sort | Danne, Thomas |
collection | PubMed |
description | People with diabetes are at greater risk for negative outcomes from COVID-19. Though this risk is multifactorial, poor glycaemic control before and during admission to hospital for COVID-19 is likely to contribute to the increased risk. The COVID-19 pandemic and restrictions on mobility and interaction can also be expected to impact on daily glucose management of people with diabetes. Telemonitoring of glucose metrics has been widely used during the pandemic in people with diabetes, including adults and children with T1D, allowing an exploration of the impact of COVID-19 inside and outside the hospital setting on glycaemic control. To date, 27 studies including 69,294 individuals with T1D have reported the effect of glycaemic control during the COVID-19 pandemic. Despite restricted access to diabetes clinics, glycaemic control has not deteriorated for 25/27 cohorts and improved in 23/27 study groups. Significantly, time in range (TIR) 70–180 mg/dL (3.9–10 mmol/L) increased across 19/27 cohorts with a median 3.3% (− 6.0% to 11.2%) change. Thirty per cent of the cohorts with TIR data reported an average clinically significant TIR improvement of 5% or more, possibly as a consequence of more accurate glucose monitoring and improved connectivity through telemedicine. Periodic consultations using telemedicine enables care of people with diabetes while limiting the need for in-person attendance at diabetes clinics. Reports that sustained hyperglycaemia and early-stage diabetic ketoacidosis may go untreated because of the lockdown and concerns about potential exposure to the risk of infection argue for wider access to glucose telemonitoring. Therefore, in this paper we have critically reviewed reports concerning use of telemonitoring in the acute hospitalized setting as well as during daily diabetes management. Furthermore, we discuss the indications and implications of adopting telemonitoring and telemedicine in the present challenging time, as well as their potential for the future. |
format | Online Article Text |
id | pubmed-8327601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-83276012021-08-02 Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future Danne, Thomas Limbert, Catarina Puig Domingo, Manel Del Prato, Stefano Renard, Eric Choudhary, Pratik Seibold, Alexander Diabetes Ther Review People with diabetes are at greater risk for negative outcomes from COVID-19. Though this risk is multifactorial, poor glycaemic control before and during admission to hospital for COVID-19 is likely to contribute to the increased risk. The COVID-19 pandemic and restrictions on mobility and interaction can also be expected to impact on daily glucose management of people with diabetes. Telemonitoring of glucose metrics has been widely used during the pandemic in people with diabetes, including adults and children with T1D, allowing an exploration of the impact of COVID-19 inside and outside the hospital setting on glycaemic control. To date, 27 studies including 69,294 individuals with T1D have reported the effect of glycaemic control during the COVID-19 pandemic. Despite restricted access to diabetes clinics, glycaemic control has not deteriorated for 25/27 cohorts and improved in 23/27 study groups. Significantly, time in range (TIR) 70–180 mg/dL (3.9–10 mmol/L) increased across 19/27 cohorts with a median 3.3% (− 6.0% to 11.2%) change. Thirty per cent of the cohorts with TIR data reported an average clinically significant TIR improvement of 5% or more, possibly as a consequence of more accurate glucose monitoring and improved connectivity through telemedicine. Periodic consultations using telemedicine enables care of people with diabetes while limiting the need for in-person attendance at diabetes clinics. Reports that sustained hyperglycaemia and early-stage diabetic ketoacidosis may go untreated because of the lockdown and concerns about potential exposure to the risk of infection argue for wider access to glucose telemonitoring. Therefore, in this paper we have critically reviewed reports concerning use of telemonitoring in the acute hospitalized setting as well as during daily diabetes management. Furthermore, we discuss the indications and implications of adopting telemonitoring and telemedicine in the present challenging time, as well as their potential for the future. Springer Healthcare 2021-08-02 2021-09 /pmc/articles/PMC8327601/ /pubmed/34338994 http://dx.doi.org/10.1007/s13300-021-01114-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Danne, Thomas Limbert, Catarina Puig Domingo, Manel Del Prato, Stefano Renard, Eric Choudhary, Pratik Seibold, Alexander Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future |
title | Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future |
title_full | Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future |
title_fullStr | Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future |
title_full_unstemmed | Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future |
title_short | Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future |
title_sort | telemonitoring, telemedicine and time in range during the pandemic: paradigm change for diabetes risk management in the post-covid future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327601/ https://www.ncbi.nlm.nih.gov/pubmed/34338994 http://dx.doi.org/10.1007/s13300-021-01114-x |
work_keys_str_mv | AT dannethomas telemonitoringtelemedicineandtimeinrangeduringthepandemicparadigmchangefordiabetesriskmanagementinthepostcovidfuture AT limbertcatarina telemonitoringtelemedicineandtimeinrangeduringthepandemicparadigmchangefordiabetesriskmanagementinthepostcovidfuture AT puigdomingomanel telemonitoringtelemedicineandtimeinrangeduringthepandemicparadigmchangefordiabetesriskmanagementinthepostcovidfuture AT delpratostefano telemonitoringtelemedicineandtimeinrangeduringthepandemicparadigmchangefordiabetesriskmanagementinthepostcovidfuture AT renarderic telemonitoringtelemedicineandtimeinrangeduringthepandemicparadigmchangefordiabetesriskmanagementinthepostcovidfuture AT choudharypratik telemonitoringtelemedicineandtimeinrangeduringthepandemicparadigmchangefordiabetesriskmanagementinthepostcovidfuture AT seiboldalexander telemonitoringtelemedicineandtimeinrangeduringthepandemicparadigmchangefordiabetesriskmanagementinthepostcovidfuture |